
Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn.
What’s the opportunity?
Parabilis Medicines, Inc. is seeking a highly talented and motivated Principal Product Manager to help define and implement the vision, roadmap, and delivery of the informatics, AI, and data products that power our organization. Reporting to the Senior Director of Software and Data Engineering, you will be a genuine thought partner to engineering and scientific leadership, shaping where we go as well as driving how we get there. You will work across the company to translate stakeholder needs into pragmatic, well-sequenced plans, and partner closely with software engineers and data scientists to ship software that users actually adopt. This is a senior individual contributor role that will lead through influence rather than authority: prioritizing work, defining requirements across, and holding cross-functional teams accountable for delivery, without direct people management responsibilities.
You’ll partner day-to-day with a data science and engineering team that is a central pillar of Parabilis’s innovative discovery platform, and with the research teams developing medicines for “undruggable” disease targets. Our data science team is an integrated team ranging from computational biology, bioinformatics, computational drug discovery, research informatics and data engineering. We work at the interface of chemistry, biology, clinical and computational sciences, and are responsible for all aspects of data science from building the discovery pipeline to supporting and developing our discovery platform. Your remit spans this scientific work and the broader portfolio of AI-driven tools we are building for every function across the company.
Parabilis Medicines is a team of passionate pioneers who are trailblazing the future of precision medicine with the aim of making a meaningful difference in the lives of patients. The company is committed to promoting an inspiring and flourishing working environment for all employees across the business, in all departments, and driving innovation for patient benefit.
The base salary range for this position is $170,000-$205,000 per year, depending on experience, qualifications, and internal practices. Parabilis’s total compensation package also includes an annual target bonus, equity, and a comprehensive suite of competitive benefits designed to support our employees’ overall well-being.
As an equal opportunity employer, Parabilis Medicines values an inclusive workplace and welcomes applicants of all backgrounds and experiences. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law.
30 Acorn Park Drive | Cambridge, MA 02140 | www.parabilismed.com

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact.